Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

FDA granted Fast Track designation to Debiopharm for the use of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123) for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer.

April 24, 2026

Vol.52 No.16

In Brief

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

The American Association for Cancer Research will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026 to be held April 17-22 in San Diego.

April 17, 2026

Vol.52 No.15

Clinical Roundup

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

For years, a central debate in tobacco policy has been whether taxing e-cigarettes might unintentionally drive vapers back to traditional cigarettes.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Lung cancer surgery safe for many patients over 80, Mount Sinai study finds

Adults aged 80 and older with early-stage lung cancer can safely undergo surgery and achieve outcomes comparable to younger patients, challenging longstanding assumptions about age and cancer treatment, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center.

April 10, 2026

Vol.52 No.14

Clinical Roundup

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

March 27, 2026

Vol.52 No.12

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

YOU MAY BE INTERESTED IN

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

Lung cancer surgery safe for many patients over 80, Mount Sinai study finds

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Renew today!

Subscriber content

Never miss an issue!

Login